NDA 205834 · Gilead Sciences INC
Harvoni
Ledipasvir, Sofosbuvir · Oral · Hepatitis C Virus NS5A Inhibitor; Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Oct 10, 2014
Approved uses
12
Original approval plus efficacy supplements
Registered trials
112
24 Phase 3, 0 recruiting
FAERS reports
19,121
7,455 serious, 780 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with HARVONI. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated [see Warnings and Precautions (5.1) ]. WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV See full prescribing information for complete boxed warning. Hepatitis B virus...
What it is approved for
From the label in effect Nov 6, 2026.
HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) [see Dosage and Administration (2.2 and 2.3) and Clinical Studies (14) ] : genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin HARVONI is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older: Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis Genotype 1 infection with decompensated cirrhosis, in combination with ribavirin Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin. ( 1 )
Mechanism: HARVONI is a fixed-dose combination of ledipasvir and sofosbuvir, which are direct-acting antiviral agents against the hepatitis C virus [see Microbiology (12.4) ].
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 15, 2019 Supplement 28 · Efficacy LetterLabel
- Aug 28, 2019 Supplement 29 · Efficacy · priority review OrphanLabelLetter
- Apr 7, 2017 Supplement 17 · Efficacy · priority review LabelLetterPediatric Medical Review
- Feb 12, 2016 Supplement 9 · Efficacy · priority review LabelSummary ReviewLetter
- Feb 12, 2016 Supplement 7 · Efficacy · priority review Summary ReviewLetterLabel
- Feb 12, 2016 Supplement 8 · Efficacy · priority review LabelSummary ReviewLetter
- Nov 12, 2015 Supplement 5 · Efficacy · priority review LabelLetter
- Nov 12, 2015 Supplement 3 · Efficacy · priority review LabelLetter
- Nov 12, 2015 Supplement 6 · Efficacy · priority review LetterLabel
- Nov 12, 2015 Supplement 4 · Efficacy · priority review LabelLetter
- Nov 12, 2015 Supplement 2 · Efficacy · priority review LabelLetter
- Oct 10, 2014 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelBreakthrough therapyLabelReviewSummary Review
2 products under this application
- HARVONI · LEDIPASVIR 90MG; SOFOSBUVIR 400MG · TABLET, ORAL · Prescription
- HARVONI · LEDIPASVIR 45MG; SOFOSBUVIR 200MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ledipasvir" as an intervention, any sponsor and status, largest first.
- Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab ModelStatus unknown
Post Graduate Institute of Medical Education and Research, ChandigarhAcademic, hospital or other
NCT03488485 · 50,000 participants (planned) · Start Jun 18, 2016 · Primary completion Dec 2020
Drug: Direct Acting Antivirals · For: Chronic Hepatitis c
Sites: Chandigarh, India
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C InfectionPivotal-lookingCompleted
Tanta UniversityAcademic, hospital or other
NCT02992457 · 10,000 participants · Start Jan 2015 · Primary completion Dec 2018
Drug: Sofosbuvir; Ribavirin and 6 more · For: Hepatitis C
Sites: Tanta, Egypt · 2 sites in all
- Study of Oral Treatments for Hepatitis CPivotal-lookingCompleted
University of FloridaAcademic, hospital or other
NCT02786537 · 1,275 participants · Start Jun 2016 · Primary completion Jun 13, 2019
Drug: SOF/LDV (sofosbuvir/ledipasvir); PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only) and 2 more · For: Chronic Hepatitis C
Sites: Little Rock, Arkansas; Palo Alto, California; San Diego, California · 38 sites in all
- Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis CPivotal-lookingStatus unknown
Sherief Abd-ElsalamAcademic, hospital or other
NCT03402165 · 1,200 participants (planned) · Start Jan 1, 2017 · Primary completion Dec 1, 2022
Drug: Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir · For: Hepatitis C
Sites: Tanta, Egypt
- Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCVPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01701401 · 870 participants · Start Sep 2012 · Primary completion Mar 2014
Drug: LDV/SOF; RBV · For: Chronic Hepatitis C Virus
Sites: Birmingham, Alabama; La Jolla, California; Long Beach, California · 88 sites in all
- Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)Pivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01851330 · 647 participants · Start May 2013 · Primary completion Dec 2013
Drug: LDV/SOF; RBV · For: Chronic Hepatitis C Virus
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 52 sites in all
National Institutes of Health Clinical Center (CC)NIH
NCT02339038 · 600 participants · Start Jan 7, 2015 · Primary completion Jun 15, 2016
Drug: Ledipasvir 90 mg and Sofosbuvir 400 mg · For: HCV HIV
Sites: Washington D.C., District of Columbia · 2 sites in all
- Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV InfectionPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01768286 · 441 participants · Start Jan 2013 · Primary completion Nov 2013
Drug: LDV/SOF; RBV · For: Chronic Hepatitis C Virus
Sites: Phoenix, Arizona; Tucson, Arizona; La Jolla, California · 53 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue4,131
- headache3,707
- nausea1,242
- drug ineffective1,140
- diarrhoea913
- hepatitis c887
- insomnia835
- vomiting442
- dizziness440
- drug dose omission436
- hepatocellular carcinoma402
- treatment failure374
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2013 | 1 |
| 2014 | 125 |
| 2015 | 4,134 |
| 2016 | 5,147 |
| 2017 | 4,537 |
| 2018 | 2,885 |
| 2019 | 1,344 |
| 2020 | 414 |
| 2021 | 221 |
| 2022 | 160 |
| 2023 | 68 |
| 2024 | 34 |
| 2025 | 24 |
| 2026 | 26 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Harvoni (Ledipasvir/Sofosbuvir)
2024 spending
$35.9M
Beneficiaries
498
1,174 claims
Per beneficiary
$72,174
$1,073.72 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $243,154,493 |
| 2021 | $143,191,082 |
| 2022 | $77,783,313 |
| 2023 | $54,963,199 |
| 2024 | $35,942,415 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cost-effectiveness of treating hepatitis C in Seychelles.
Adeline NJF, Geue C, Hermami MR · Pan Afr Med J 2019 · Systematic Review
- Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection.
Asahina Y, Itoh Y, Ueno Y, et al. · Liver Int 2018 · Clinical Trial, Phase III, Multicenter Study
- Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm.
Cuadrado A, Llerena S, Cobo C, et al. · Am J Gastroenterol 2018 · Clinical Trial, Phase IV, Research Support, Non-U.S. Gov't
- Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1.
Zhu GQ, Zou ZL, Zheng JN, et al. · Medicine (Baltimore) 2016 · Research Support, Non-U.S. Gov't, Systematic Review
- Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus.
Chuang WL, Chien RN, Peng CY, et al. · J Gastroenterol Hepatol 2016 · Clinical Trial, Phase III, Multicenter Study
- Generic Ledipasvir-Sofosbuvir Treatment for Adolescents With Chronic Hepatitis C Virus Infection.
Fouad HM, Sabry MA, Ahmed A, et al. · J Pediatric Infect Dis Soc 2020 · Clinical Trial
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.